The Clinical Accuracy of the BÜHLMANN fCAL ELISA in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome: A Multicenter Prospective Case–Control Study
| Autor: | Athos Bousvaros, Alanna Grob, Eugene Greenberg, David A Florez, Ashutosh Kumar, Felix Tiongco, James Leavitt, Jeffrey A Berinstein, Razvan Arsenescu, Keith Friedenberg, Calen A. Steiner, Robert Hardi, Shahriar Sedghi, K.T. Park, Alison Fint, Anthony Lembo, Peter Kupchak, Peter D.R. Higgins |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Leukocyte L1 Antigen Complex business.industry Gastroenterology Case-control study medicine.disease Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030211 gastroenterology & hepatology 030212 general & internal medicine business Irritable bowel syndrome Feces |
| Zdroj: | Crohn's & Colitis 360. 1 |
| ISSN: | 2631-827X |
| DOI: | 10.1093/crocol/otz037 |
| Popis: | Background Fecal calprotectin (fCAL) is a noninvasive biomarker used to differentiate between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Methods A multicenter prospective case–control study evaluating the BÜHLMANN fCAL enzyme-linked immunosorbent assay (ELISA) was conducted in 478 subjects. Sensitivity, specificity, predictive values, and area under the receiver operator characteristic (AuROC) curve are reported and compared to another device. Results In differentiating IBD from IBS, the BÜHLMANN fCAL ELISA is very sensitive (93.3%) at a cutoff 160 μg/g (AuROC 0.933). Conclusions The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|